TME Pharma N.V. (FR:ALTME)
:ALTME
Want to see FR:ALTME full AI Analyst Report?
ALTME Stock Chart & Stats
€0.06
<€0.01(2.26%)
At close: 4:00 PM EST
€0.06
<€0.01(2.26%)
Day’s Range― - ―
52-Week Range€0.05 - €0.15
Previous CloseN/A
Volume26.06K
Average Volume (3M)547.76K
Market Cap
€7.61M
Enterprise Value€8.75M
Total Cash (Recent Filing)€2.02M
Total Debt (Recent Filing)€2.66M
Price to Earnings (P/E)―
Beta-0.24
Next Earnings
Oct 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding94,188,980
10 Day Avg. Volume795,319
30 Day Avg. Volume547,758
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-3.89
Price to Sales (P/S)0.00
P/FCF Ratio-1.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.15
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Oncology R&D NicheA clear strategic focus on the tumor microenvironment and difficult-to-treat cancers (including brain tumors) aligns the company with durable unmet needs in oncology. This specialization concentrates R&D resources, can create differentiated IP, and targets markets with sustained demand for novel therapies.
Clinical-stage PipelineBeing clinical-stage implies programs have advanced beyond preclinical validation, reducing some scientific risk and positioning the company for regulatory interactions and value-inflecting trial readouts. Clinical progress is a durable indicator of de-risking and potential for partnering/licensing outcomes.
Demonstrated Prior Burn ControlHistorical ability to materially reduce cash burn in 2021–2022 shows management can implement cost discipline and optimize spend. This operational flexibility can extend runway during funding gaps and supports long-term program sustainment compared with peers lacking such demonstrated control.
Bears Say
Weakened Balance SheetNegative shareholders’ equity and a sharp increase in absolute debt in 2025 materially raise solvency and financing risks. A shrinking asset base reduces collateral and strategic optionality, making the company more dependent on external capital and less resilient to funding stress over the medium term.
Persistent Cash Burn And Funding RelianceConsistent negative operating and free cash flow across years indicates structural cash burn tied to core operations. Renewed deterioration in 2025 heightens financing needs, meaning future R&D and trials depend on recurring external funding rounds which can dilute shareholders and constrain long-term strategy execution.
Pre-commercial With No Durable RevenueThe absence of recurring revenue and structural operating losses mean the company has no internal cash-generation buffer. With 2025 revenue reverting to zero, commercial viability remains uncertain and the business model depends on clinical success or external partnerships to transition to sustainable revenue.
TME Pharma N.V. News
ALTME FAQ
What was TME Pharma N.V.’s price range in the past 12 months?
TME Pharma N.V. lowest stock price was €0.05 and its highest was €0.15 in the past 12 months.
What is TME Pharma N.V.’s market cap?
TME Pharma N.V.’s market cap is €7.61M.
When is TME Pharma N.V.’s upcoming earnings report date?
TME Pharma N.V.’s upcoming earnings report date is Oct 29, 2026 which is in 139 days.
How were TME Pharma N.V.’s earnings last quarter?
Currently, no data Available
Is TME Pharma N.V. overvalued?
According to Wall Street analysts TME Pharma N.V.’s price is currently Overvalued.
Does TME Pharma N.V. pay dividends?
TME Pharma N.V. does not currently pay dividends.
What is TME Pharma N.V.’s EPS estimate?
TME Pharma N.V.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TME Pharma N.V. have?
TME Pharma N.V. has 94,188,980 shares outstanding.
What happened to TME Pharma N.V.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of TME Pharma N.V.?
Currently, no hedge funds are holding shares in FR:ALTME
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
TME Pharma N.V.
TME Pharma N.V., a biopharmaceutical company in the clinical development stage based in Berlin, Germany, is dedicated to pioneering innovative therapeutic solutions for cancer. The company leverages its unique Spiegelmer platform to advance a pipeline of investigational drug candidates. Its primary oncology asset, NOX-A12, is currently being evaluated in clinical studies as a combination therapy for a range of challenging cancers, including metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. Beyond its cancer-focused efforts, TME Pharma also developed NOX-E36, which has successfully concluded Phase 1/2 clinical trials for diabetic nephropathy. The company has formed a strategic collaboration with Merck Sharp & Dohme Corp. to explore NOX-A12 in combination with Keytruda and two different chemotherapy protocols as a second-line intervention for patients battling metastatic pancreatic cancer. Founded in 1997, the organization adopted its current name, TME Pharma N.V., in July 2022, having previously operated as NOXXON Pharma N.V.
Technical Analysis
Innate Pharma SA
―
Nanobiotix
―
Transgene
―
OSE Immunotherapeutics SA
―
Cellectis SA
―